Adrian Newman-Tancredi

Co-Founder and Chief Executive Officer of a bioscience company (Neurolixis) developing clinical-stage drugs for treatment of neurological and psychiatric CNS disorders. Adrian has over 25 years' experience of neuroscience research and his current work is focused on treatments for Parkinson's disease and Rett syndrome. Prior to joining Neurolixis, he was Director of Neurobiology at Pierre Fabre Laboratories where he led programs that identified novel antipsychotics, antidepressants and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology group at the Servier Research Institute where he investigated signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Adrian's work include milnacipran (Savella ®), piribedil (Trivastal ®), agomelatine (Valdoxan ®), levomilnacipran (Fetzima ®) and befiradol (NLX-112). In addition, Adrian led the program that discovered the first-in-class serotonergic "biased agonists", NLX-101 (F15599) and NLX-204. Adrian has published over 190 articles in peer-reviewed journals, co-authored a dozen patents on NCEs and given presentations to a wide variety of audiences. He serves as European Councillor of the International Society for Serotonin Research.